Exhibit 99.1

 

Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates

 

Marketing Submissions for Galafold® (migalastat HCl) for Fabry Disease Under Review

in Europe and on Track for Filing in 2H15 in United States

 

2Q15 Equity Financing Significantly Strengthens Balance Sheet; More Than $350M Cash on Hand

 

International Commercial Leadership Team Nearly Complete

 

Phase 1/2 Clinical Study Initiation of Next-Generation Pompe ERT in 2H15

 

CRANBURY, NJ, August 5, 2015 — Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced financial results for the second quarter ended June 30, 2015. The Company also provided program updates and reiterated full-year 2015 net cash spend guidance of $100 million to $110 million.

 

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “During the second quarter we made great progress towards our vision of building one of the world’s leading biotechnology companies focused on rare and orphan diseases.  As part of fulfilling that vision and mission, we now have in place a world class international business and commercial leadership team. Our first marketing application for Galafold for Fabry disease is now under review in Europe, and we plan to submit our U.S. marketing application in the second half of this year. We have also made significant progress toward clinical studies with our next-generation Pompe enzyme replacement therapy. I am proud to report that this next-generation biologic has now completed the first GMP production run and has maintained its exceptionally high levels of mannose-6 phosphate and proper glycosylation. The Pompe program remains on track with all IND-enabling toxicology studies also nearly complete as we advance towards initiation of clinical studies in patients by the end of 2015.”

 

Financial Highlights for Second Quarter Ended June 30, 2015

 

·                       Cash, cash equivalents, and marketable securities totaled $361.4 million at June 30, 2015, compared to $169.1 million at December 31, 2014.

·                       Total operating expenses increased to $26.9 million compared to $14.7 million for the second quarter 2014, primarily due to increases in preclinical and clinical development costs on the Fabry monotherapy and Pompe ERT programs.

·                       Net loss was $27.1 million, or $0.27 per share, compared to a net loss of $14.6 million, or $0.22 per share, for the second quarter 2014.

 

2015 Financial Guidance

 

Cash, cash equivalents, and marketable securities totaled $361.4 million at June 30, 2015 compared to $169.1 million at December 31, 2014. The Company’s balance sheet was strengthened during the second quarter of 2015 with a $258.8 million follow-on public offering. Amicus continues to expect full-year 2015 net cash spend between $100 million and $110 million. The current cash position is projected to fund operations into 2017.

 

Organizational Update

 

Amicus is building its commercial infrastructure in both the U.S. and Europe to support the potential 2016 launch of the oral pharmacological chaperone Galafold as a personalized medicine for Fabry patients who have amenable mutations. The Company continues to hire industry leaders who are experienced in building commercial teams to launch innovative therapies at some of the most successful and respected companies in biotechnology and orphan diseases. There are currently regional leaders in place who are responsible for the key commercial regions around the globe as well as functional heads in the areas of commercial operations, medical affairs, and marketing among others who are actively preparing to launch Galafold.

 

Program Highlights

 

Fabry Franchise

 

Amicus has made significant progress executing its global regulatory and launch strategy for Galafold. During the second quarter, the Company submitted a marketing authorization application (MAA) for Galafold under accelerated assessment.

 

 

On June 25, 2015, the MAA was validated by the European Medicines Agency (EMA) and review began under the Centralized Procedure. The MAA validation also triggered the initiation of the global regulatory process in several additional geographies. In the U.S., a pre-New Drug Application (pre-NDA) meeting is scheduled for the third quarter with the Food and Drug Administration (FDA) to discuss the content of the planned NDA (Subpart H) and proposed Phase 4 post-marketing commitments for Galafold in the second half of this year.

 

Positive Phase 3 data in both treatment-naïve and ERT-switch patients have shown that treatment with Galafold has resulted in reductions in disease substrate, stability of kidney function, reduction in cardiac mass, and a positive impact in patient-reported outcomes in patients with amenable mutations. For Fabry patients who do not have amenable mutations and cannot take monotherapy, Amicus is advancing migalastat in combination with ERT.

 

Anticipated 2015 Fabry Franchise Milestones:

 

·                       Pre-NDA meeting with FDA (3Q15)

 

·                       NDA submission for Galafold in U.S. (2H15)

 

·                       Initiation of Phase 2 study of oral migalastat co-administered with currently marketed ERTs (2H15)

 

·                       Internal development underway of next-generation ERT (Fabry cell line for co-formulation with migalastat)

 

Next-Generation ERT for Pompe Disease (ATB200 + Chaperone)

 

During the second quarter, Amicus completed the first good manufacturing practice (GMP) production run of ATB200, a next-generation Pompe ERT.  This is a significant milestone as Amicus advances toward clinical study initiation in Pompe patients. Additional GMP manufacturing runs will occur during the second half of 2015 to build further supply for clinical studies.

 

Amicus is leveraging its biologics capabilities and CHART™ (Chaperone-Advanced Replacement Therapy) platform to develop ATB200. This next-generation ERT consists of a uniquely engineered recombinant human acid alpha-glucosidase (rhGAA) enzyme with an optimized carbohydrate structure to enhance uptake, administered with a pharmacological chaperone enhancer to improve activity and stability.

 

Anticipated 2015 Pompe Program Milestones:

 

·                       Start of observational clinical study in Pompe patients (3Q15)

 

·                       Meetings with US and EU regulatory authorities to discuss clinical development plan (3Q15)

 

·                       Phase 1/2 clinical study initiation to investigate the next-generation treatment paradigm for Pompe patients, ATB200 + chaperone (4Q15)

 

Conference Call and Webcast

 

Amicus Therapeutics will host a conference call and audio webcast today, August 5, 2015 at 5:00 p.m. ET to discuss second quarter 2015 financial results and program updates. Interested participants and investors may access the conference call at 5:00 p.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

 

An audio webcast and slide presentation can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://www.amicusrx.com, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software. A telephonic replay of the call will be available for seven days beginning at 8:00 p.m. ET today. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 98584713.

 

About Amicus Therapeutics

 

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. Amicus’ lead programs in development include the small molecule pharmacological chaperone Galafold as a monotherapy for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS I.

 

Forward-Looking Statements

 

This press release contains, and the accompanying conference call will contain, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus’ candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus’ candidate drug products, financing plans, and the projected cash position for the Company. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “potential,” “plan,” “targets,” “likely,” “may,” “will,”

 

 

“would,” “should” and “could,” and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company’s cash position, actual results may differ based on market factors and the Company’s ability to execute its operational and budget plans. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2014. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

 

CONTACTS:

 

Investors/Media:

Amicus Therapeutics

Sara Pellegrino

Director, Investor Relations

spellegrino@amicusrx.com

(609) 662-5044

 

Media:

Pure Communications

Dan Budwick

dan@purecommunicationsinc.com

(973) 271-6085

 

 

Table 1

 

Amicus Therapeutics, Inc.

Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

 

		Three Months						Six Months
		Ended June 30,						Ended June 30,
		2015			2014			2015			2014
Revenue:
Research revenue		—			$	475		—			$	931
Total revenue		—			475			—			931
Operating Expenses:
Research and development		$	17,234		$	9,978		$	33,347		$	19,970
General and administrative		8,278			4,753			14,705			9,929
Changes in fair value of contingent consideration payable		100			(305		)	1,100			200
Restructuring charges		26			(81		)	36			(89		)
Loss on extinguishment of debt		952			—			952			—
Depreciation		353			396			861			808
Total operating expenses		26,943			14,741			51,001			30,818
Loss from operations		(26,943		)	(14,266		)	(51,001		)	(29,887		)
Other income (expenses):
Interest income		158			36			329			78
Interest expense		(338		)	(374		)	(710		)	(729		)
Other expense		(10		)	(10		)	(39		)	(19		)
Net loss		$	(27,133	)	$	(14,614	)	$	(51,421	)	$	(30,557	)
Net loss per common shares — basic and diluted		$	(0.27	)	$	(0.22	)	$	(0.53	)	$	(0.46	)
Weighted-average common shares outstanding — basic and diluted		99,994,125			67,212,764			97,888,573			65,799,059

 

 

Table 2

 

Amicus Therapeutics, Inc.

Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share amounts)

 

		June 30,  2015			December 31,  2014
Assets:
Current assets:
Cash and cash equivalents		$	249,023		$	24,074
Investments in marketable securities		112,396			127,601
Prepaid expenses and other current assets		3,578			2,902
Total current assets		364,997			154,577
Investments in marketable securities		—			17,464
Property and equipment, less accumulated depreciation of $12,381 and $11,520 at June 30, 2015 and December 31, 2014, respectively		3,379			2,811
In-process research & development		23,000			23,000
Goodwill		11,613			11,613
Other non-current assets		924			502
Total Assets		$	403,913		$	209,967
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses		$	16,901		$	16,345
Current portion of secured loan		—			3,840
Total current liabilities		16,901			20,185
Deferred reimbursements		36,620			36,620
Secured loan, less current portion		—			10,510
Contingent consideration payable		11,800			10,700
Deferred tax liability		9,186			9,186
Other non-current liability		504			588
Commitments and contingencies
Stockholders’ equity:
Common stock, $.01 par value, 250,000,000 shares authorized, 118,367,319 shares issued and outstanding at June 30, 2015, 125,000,000 shares authorized, 95,556,277 shares issued and outstanding at December 31, 2014		1,241			1,015
Additional paid-in capital		826,582			568,743
Accumulated other comprehensive income		(52		)	(132		)
Accumulated deficit		(498,869		)	(447,448		)
Total stockholders’ equity		328,902			122,178
Total Liabilities and Stockholders’ Equity		$	403,913		$	209,967

 

FOLD—G